Breast Cancer

Breast cancer risk was estimated among survivors of pediatric cancer who were treated with chest radiation with a newly developed and validated breast cancer risk prediction model.

The FDA has given a fast track designation to gedatolisib as a treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

“If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.”

In this episode of "Oncology Peer Review On-The-Go," Amy Comander, MD, spoke with CancerNetwork regarding important developments in breast cancer that took place in 2021 and key clinical trials that read out throughout the year.

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

Enobosarm was granted fast track designation by the FDA for the treatment of patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Experts provide clinical pearls to the audience on treating patients with breast cancer.

The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.

Amy Comander, MD, shares her thoughts on key developments in breast cancer care that took place in 2021, and reflects on what the future might hold for this patient population

Remedying gaps in knowledge and implementing strategies for financial toxicity mitigation are important for optimizing breast cancer treatment.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.

Paolo Tarantino, MD, hosted a Twitter Takeover during the San Antonio Breast Cancer Symposium where he discussed abstract presentations and key takeaways in a #CNRealTimeReport.

CancerNetwork® looks back on some of the promising, ongoing pieces of clinical research within the breast cancer space from 2021.

Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.

Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.

Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.

The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.

Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.

Patients with gremlin BRCA1/2 mutations and high-risk HER2-negative early breast cancer can have amenable adverse effects after being treated with chemotherapy before utilize olaparib.

Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms

Patients with hormone receptor-positive breast cancer who were treated with samuraciclib plus fulvestrant saw tumor activity.

Findings from the SqeDCIS trial indicated that DCISionRT was predictive of radiotherapy benefit in patients with ductal carcinoma in situ of the breast.

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.